Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

 

Placebo

AZD7594

(n = 52)

58 μg (n = 34)

250 μg (n = 34)

800 μg (n = 34)

Demographics

 Age, years Mean (SD)

51 (12)

51 (12)

50 (12)

51 (12)

 Male n (%)

44 (84.6%)

26 (76.5%)

30 (88.2%)

28 (82.3%)

 White n (%)

51 (98.1%)

33 (97.1%)

33 (97.1%)

34 (100%)

 Black n (%)

1 (1.92%)

1 (2.94%)

1 (2.94%)

0 (0.00)

 BMII kg/m2 Mean (SD)

27 (3)

27 (4)

28 (3)

27 (3)

Asthma Characteristics

 Prebronchodilator FEV1 (L), Mean (SD)

2.53 (0.74)

2.54 (0.73)

2.59 (0.72)

2.55 (0.69)

 % patients meeting FEV1 reversibility criteriaa

78.8%

88.2%

73.5%

70.6%

 ACQ-5 score mean (SD)

1.2 (0.7)

1.2 (0.6)

1.2 (0.6)

1.2 (0.7)

 Asthma symptom score (SD)

0.8 (0.5)

08 (0.5)

0.8 (0.5)

0.8 (0.5)

 FENO ppb (SD)

57 (45)

60 (47)

53 (34)

57 (39)

  1. aReversibility was defined as ≥12% and ≥ 200 ml increase from pre-bronchodilator FEV1, ACQ-5 Asthma Control Questionnaire-5, BMI body mass index, FENO Fraction exhaled nitric oxide, kg kilogram, m meter, SD standard deviation